In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

After three years, Roche gains full ownership of Foundation Medicine for $2.4bn

Executive Summary

Roche acquired the remaining 43% stake of publicly traded tumor genomic profiling company Foundation Medicine Inc. (FMI) that it didn’t already own for $2.4bn on a fully diluted basis (total company value of $5.3bn on a fully diluted basis). Roche paid $137 in cash per share, a 34% premium.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Services
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies